Company Filing History:
Years Active: 2021-2022
Title: Innovations of Kangwon Jang
Introduction
Kangwon Jang is a notable inventor based in Yongin-si, South Korea. He has made significant contributions to the field of biotechnology, particularly in the development of antisense oligonucleotides. With a total of 3 patents, his work focuses on innovative solutions for medical conditions related to gene expression.
Latest Patents
One of his latest patents is the HIF 1-alpha antisense oligonucleotides. This invention provides peptide nucleic acid derivatives that target a specific part of the human HIF-1α pre-mRNA. These derivatives are designed to potently induce exon skipping, resulting in splice variants of HIF-1α mRNA in cells. This innovation holds promise for treating conditions involving the overexpression of HIF-1α. Another significant patent is the SNAP25 antisense oligonucleotides. This invention also involves peptide nucleic acid derivatives that target a 3' splice site of the human SNAP25 pre-mRNA. These derivatives can induce splice variants of the human SNAP25 mRNA in cells, offering potential treatments for dermatological conditions related to the expression of the human SNAP25 protein through topical administration.
Career Highlights
Kangwon Jang is currently associated with Olipass Corporation, where he continues to advance his research and development efforts. His work is characterized by a strong focus on innovative therapeutic approaches that leverage the power of genetic engineering.
Collaborations
Kangwon collaborates with talented individuals in his field, including Daram Jung and Bongjun Cho. Their combined expertise contributes to the success of their projects and the advancement of their research.
Conclusion
Kangwon Jang's contributions to biotechnology through his innovative patents demonstrate his commitment to addressing complex medical challenges. His work continues to pave the way for new therapeutic options in the field.